Effects of valsartan on peritoneal function in patients undergoing peritoneal dialysis

Abstract

Objective To investigate the effects of the angiotensin receptor blocker (ARB) valsartan on peritoneal function in patients undergoing peritoneal dialysis.Methods Fifty-one patients undergoing continuous ambulatory peritoneal dialysis (CAPD) in our department were randomly assigned to the valsartan group (n =28) or the control group (n =23).Those of the control group were administered with antihypertensive agents except ACE inhibitors and angiotensin receptor blockers (ARBs).At baseline and 1 year,estimated glomerular filtration rate (eGRF),ultrafiltration (UF),dialysis/plasma creatinine (D/Pcr) and D/D0 were measured.In the PET,transforming growth factor-β1 (TGF-β1) and vascular endothelial growth factor (VEGF) in the overnight dialysate were tested by using ELISE.t test was used for data analysis.Reesult Baseline clinical characteristics were not significantly different between the two groups.At 1 year,eGRF was decreased to (3.1 ± 1.8) ml/min in the valsartan group and to (2.1 ± 1.9) ml/min in the control group (P ＜ 0.05).The ultrafiltration volume was higher in the control group than the valsartan group ((391 ± 220) vs (445 ± 209) ml/4 h,P ＜ 0.05).TGF-β1 and VEGF of the 2 groups were increased,while the change in the control group showed statistically significant difference (P ＜ 0.05).Conclusion In CAPD patients,valsartan can delay the occurrence of altrafiltration failure and protect against peritoneal fibrosis. Key words: Peritoneal dialysis; Residual renal function; Peritoneal fibrosis; Angiotensin receptor blocker; Valsartan